Moleculin Biotech is trading at $0.38 (10.2% down) following a sharp pullback in thin after-hours trading.
- The decline extends a multi-day selloff triggered by the company's discounted $9.3 million public offering.
- Traders remain cautious due to significant share dilution and the enlarged share count resulting from the capital raise.
- The stock continues to face a lingering price overhang as the market absorbs the impact of the recent financing.